Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Himisha Beltran(Dana-Farber Cancer Institute), Martin Gleave(University of British Columbia), Michael J. Morris(Dana-Farber Cancer Institute), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School), Michael Sigouros(Cornell University), Ladan Fazli, Matti Annala(Tampere University), Andrea Sboner(Cornell University), Colin C. Collins(University of British Columbia), Susan Halabi(Duke Medical Center), Alexander W. Wyatt(University of British Columbia), Adam Donoghue(Cornell University), Evan W. Warner(Guardant (United States)), Fan Mo(University of British Columbia), Edmund C.P. Chedgy(University Hospital Southampton NHS Foundation Trust), James A. Eastham(Memorial Sloan Kettering Cancer Center), Kevin Beja(University of British Columbia)
Cited by 75
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k